Image may be NSFW.
Clik here to view.
Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin.
The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Aradigm lands NIH grant for inhaled, liposomal products appeared first on MassDevice.
